In endometrial cancer, certain genetic signatures are investigated as alternative biomarkers for ICIs, such as ARID1A alterations, associated with higher TILs, supporting the view that deficient ARID1A might be a potential predictor factor for ICIs efficacy [59]. The gene discussed is ARID1A; the disease is endometrial cancer.